Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

Launched by CARTESIAN THERAPEUTICS · Oct 29, 2019

Keywords

ClinConnect Summary

The Descartes-08 clinical trial is looking at a new treatment using CAR-T cells for patients with Generalized Myasthenia Gravis (MG), a condition that causes weakness in the muscles. This study is currently recruiting participants who are at least 18 years old and have been diagnosed with Generalized Myasthenia Gravis. If you are taking certain immunosuppressive medications, which help to reduce the immune system's activity, you may also be eligible to participate. However, individuals with significant unmanaged chronic illnesses or those who are pregnant or breastfeeding cannot take part in the trial.

Participants in this study will receive the Descartes-08 CAR-T cell treatment and will be monitored to see how safe it is and whether it helps improve their condition. The study is in the second phase, meaning researchers are evaluating not just safety but also how well the treatment works. If you or a loved one is considering joining, it’s important to discuss it with a healthcare provider to understand the potential benefits and risks.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient must be at least 18 years of age.
• • Patient must have Generalized Myasthenia Gravis at the time of screening.
• • Concomitant immunosuppressive drugs must be deemed necessary by the investigator.
• • Seronegative Patients are included
• Exclusion Criteria:
• • Major chronic illness that is not well managed at the time of study entry and in the opinion of the investigator may increase the risk to the patient.
• • Patient is pregnant or lactating.